Aurora Cannabis Inc. has officially announced the acquisition of MedLeaf Therapeutics, a specialized producer of medical cannabis, for a total of $215 million. This transaction comprises $125 million in cash and $90 million in Aurora common shares, reflecting a strategic move to enhance Aurora’s medical cannabis offerings.
The acquisition, detailed in a recent SEC filing, aims to broaden Aurora’s footprint in international markets, particularly in Europe and Australia, where MedLeaf already has established distribution networks. The deal is expected to finalize by August 31, 2025, pending regulatory approvals and standard closing conditions.
Miguel Martin, Chief Executive Officer of Aurora Cannabis, emphasized that this acquisition aligns with Aurora’s strategy for global growth in the medical cannabis sector, adding that MedLeaf’s products will complement Aurora’s existing portfolio.
MedLeaf Therapeutics reported an annual revenue of $78 million for the fiscal year ending December 2024. The company operates two GMP-certified production facilities, boasting a combined capacity of 35,000 kilograms annually. Aurora anticipates that this acquisition will positively impact earnings in the first full year of integration, projecting cost synergies of around $15 million through improved operational capabilities and supply chain management.
To facilitate a smooth transition, MedLeaf’s executive team will join Aurora, ensuring continuity in operations and integration of the two companies. This acquisition marks a significant step for Aurora as it seeks to strengthen its position in the growing medical cannabis market.
English 
Spanish 
German 
Czech